AbbVie and Allergan: A Closer Look at Their Merger Timeline and Closing Date
The pharmaceutical industry has been abuzz with the news of AbbVie's acquisition of Allergan, a deal that promises to create a global biopharmaceutical leader with strong positions in key therapeutic areas. As the closing date approaches, let's delve into the timeline of this significant merger and what it means for the industry and patients.
Understanding the Merger: AbbVie's Acquisition of Allergan
In June 2019, AbbVie announced its intention to acquire Allergan in a cash and stock transaction valued at approximately $63 billion. The acquisition, which is AbbVie's largest to date, aims to strengthen AbbVie's leading position in immunology and expand its offerings in areas such as neuroscience, eye care, and gastrointestinal diseases.
The Merger Timeline: Key Dates and Milestones
- June 24, 2019: AbbVie and Allergan announce the merger agreement.
- October 9, 2019: Allergan shareholders approve the merger.
- October 31, 2019: AbbVie shareholders approve the merger.
- December 16, 2019: The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expires, clearing a significant regulatory hurdle.
- Expected in Q1 2020: Closing of the transaction, subject to remaining regulatory approvals and other customary closing conditions.
The Impact of the Merger on the Industry and Patients
The combined company will have a robust pipeline, with 50 new medicines expected to be launched by 2025. This could lead to significant advancements in treating various conditions, from autoimmune diseases to eye disorders. Moreover, the merger is expected to generate substantial cost synergies, which AbbVie plans to reinvest in research and development, potentially leading to even more innovative treatments.
However, the merger also raises concerns about potential price increases for Allergan's products, which have been criticized for their high costs in the past. AbbVie has stated that it will not raise prices on Allergan's products above the inflation rate for the first two years after the merger's completion, but it remains to be seen how prices will evolve in the long term.
Regulatory Approval: The Final Hurdle Before the Closing Date
Before the merger can be finalized, it must receive approval from regulatory authorities in various countries, including the Federal Trade Commission (FTC) in the United States. The FTC has been scrutinizing the deal, focusing on potential overlaps in AbbVie's and Allergan's portfolios, particularly in the areas of immunology and eye care.
In December 2019, AbbVie announced that it had reached a deal with the FTC to address its antitrust concerns. The agreement involves AbbVie divesting certain assets, including Allergan's dry eye drug Restasis and its rights to a biosimilar to Humira, AbbVie's blockbuster drug. With this hurdle cleared, the path to the closing date appears smoother.
Looking Ahead: What the Merger Means for AbbVie and Allergan
Upon closing, the combined company will operate under the AbbVie name, with AbbVie's current CEO, Richard A. Gonzalez, continuing to lead the company. Allergan's CEO, Brent Saunders, will join AbbVie's board of directors. The merger is expected to be accretive to AbbVie's adjusted earnings per share in the first full year after closing.
The AbbVie-Allergan merger promises to reshape the pharmaceutical industry, creating a company with a strong portfolio of products and a robust pipeline. As the closing date approaches, all eyes are on the potential benefits and challenges that this merger may bring to the industry and, ultimately, to patients.
